Citations

Clear

6274 citation(s) found for "To, Andrew".

704 Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
Lichtenstein, Gary R. , Soonasra, Arif, Lawendy, Nervin, Chan, Gary , Zhang, Haiying , Wang, Wenjin , Bloom, Stuart , Loftus, Edward V. , Thorpe, Andrew J.

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S413-S414

10.14309/01.ajg.0000592352.44466.21 Get It

INTRODUCTION: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Tofacitinib safety and efficacy were demonstrated in patients (pts) with moderate to severe UC in 3 Phase 3 studies, 1 and are being evaluated in an ongoing, open-label, long-term extension (OLE) study. 2 METHODS: We present updated safety and efficacy data from the OCTAVE Open OLE study (NCT01470612; Sep 2018; database not locked) 2 in completers/treatment failures in OCTAVE Sustain (NCT01458574) or non-responders in OCTAVE Induction 1/2 (NCT01465763/NCT01458951). Week (Wk) 8 data (OCTAVE Induction 1/2) and Wk 52 (completers) or early-termination data (OCTAVE Sustain) determined eligibility. Pts in remission (total Mayo score ≤2, no individual subscore >1, rectal bleeding subscore 0) at Wk 52 of OCTAVE Sustain (central read) received tofacitinib 5 mg twice daily (BID) in the OLE study; all others received 10 mg BID. At Month 2, all pts had endoscopy, and induction non-responders with no clinical response were withdrawn. Incidence rates (IRs; unique pts with events per 100 pt-years [PY]) for adverse events (AEs) of special interest were calculated. Efficacy endpoints were derived from Mayo score (local read). RESULTS: Of 944 pts receiving ≥1 tofacitinib dose (for up to 5.5 years), 175 (18.5%) and 769 (81.5%) received 5 and 10 mg BID, respectively (454 and 1550 PY, respectively). 337 (35.7%) pts discontinued due to insufficient clinical response and 78 (8.3%) due to AEs excl. worsening UC. The most frequent AE class was infections and infestations (52.1%). The most frequent AEs were nasopharyngitis (20.3%) and worsening UC (19.5%). IRs (95% CI) for “Tofacitinib All” were: serious infections 1.61 (1.10, 2.27); herpes zoster (all) 3.35 (2.58, 4.27); major adverse cardiovascular events 0.15 (0.03, 0.44); malignancies excl. non-melanoma skin cancer (NMSC) 0.85 (0.50, 1.36); and NMSC 0.81 (0.46, 1.32), with no clustering of malignancy type. Table 1 shows AEs and IRs by dose. No new safety risks were identified. Table 2 shows efficacy data at Month 36. CONCLUSION: In pts with UC in the OLE study, no new safety risks emerged at 5.5 years vs earlier OLE analyses 2 or with tofacitinib in rheumatoid arthritis. Efficacy data continue to support long-term efficacy of tofacitinib 5 or 10 mg BID up to 36 months beyond OCTAVE Sustain.
Cervicocerebral quantitative arterial tortuosity: a biomarker of arteriopathy in children with intracranial aneurysms
Chen, Alan M., Karani, Kunal B. , Taylor, J. Michael , Zhang, Bin , Furthmiller, Andrew , Vela, Gabriel De, Leach, James L. , Vadivelu, Sudhakar , Abruzzo, Todd , Abruzzo, Todd A

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 4, 2019 | Volume: 24 | Issue: 4 | Pages: 389-396

10.3171/2019.5.peds1982 | PMID 31349231 Get It

OBJECTIVEAlthough intracranial arterial aneurysms (IAAs) of childhood are usually idiopathic, it is possible that underlying arteriopathy escapes detection when using conventional diagnostic tools. Quantitative arterial tortuosity (QAT) has been studied as a biomarker of arteriopathy. The authors analyzed cervicocerebral QAT in children with idiopathic IAAs to assess the possibility of arteriopathy.METHODSCases were identified by text-string searches of imaging reports spanning the period January 1993 through June 2017. QAT of cervicocerebral arterial segments was measured from cross-sectional studies using image-processing software. Other imaging and clinical data were confirmed by retrospective electronic record review. Children with idiopathic IAAs and positive case controls, with congenital arteriopathy differentiated according to aneurysm status (with and without an aneurysm), were compared to each other and to healthy controls without vascular risk factors.RESULTSCervicocerebral QAT was measured in 314 children: 24 with idiopathic IAAs, 163 with congenital arteriopathy (including 14 arteriopathic IAAs), and 127 healthy controls. QAT of all vertebrobasilar segments was larger in children with IAAs (idiopathic and arteriopathic forms) (p < 0.05). In children with congenital arteriopathy without an aneurysm, QAT was decreased for the distal cervical vertebral arteries and increased for the supraspinal vertebral artery relative to healthy children. QAT of specific cervicocerebral segments correlated with IAA size and rupture status.CONCLUSIONSCervicocerebral QAT is a biomarker of arteriopathy in children with IAA, even in the absence of other disease markers. Additional findings suggest a correlation of cervicocerebral QAT with IAA size and rupture status and with the presence of IAA in children with congenital arteriopathy.
Primary Prevention of Cardiovascular Disease
Jain, Atul , Jain, Atul, Davis, Andrew M.

Mayo Clinic

JAMA | October 4, 2019 | Volume: 322 | Issue: 18 | Pages: 1817

10.1001/jama.2019.15915 | PMID 31584604 Get It

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry
Amador, Catalina , Greiner, Timothy C. , Heavican, Tayla B., Smith, Lynette M. , Galvis, Karen, Lone, Waseem , Bouska, Alyssa , d’Amore, Francesco, Pedersen, Martin Bjerregård , Pileri, Stefano , Rosenwald, Andreas , Ott, German , Mottok, Anja , Lim, Soon Thye , Ong, Choon Kiat , Ondrejka, Sarah L. , Song, Joo Y. , Staudt, Louis M. , Weisenburger, Dennis D. , Chan, Wing C. , Iqbal, Javeed , Song, Joo Y , Ong, Choon Kiat , Bouska, Alyssa , Amador, Catalina , Greiner, Timothy C , Smith, Lynette , Pileri, Stefano , d'Amore, Francesco , Iqbal, Javeed , Agostinelli, Claudio , Feldman, Andrew L. , Savage, Kerry J. , Leval, Laurence de , Gaulard, Philippe , Campo, Elı́as , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M. , Lone, Waseem G

Mayo Clinic

Blood | September 27, 2019 | Volume: 134 | Issue: 24 | Pages: 2159-2170

10.1182/blood.2019000779 | PMID 31562134 Get It

One-third of peripheral T-cell lymphomas are “not otherwise specified” (PTCL-NOS), but they have been subdivided into 2 subgroups based on gene expression profiling. Amador and colleagues generated an immunohistochemical algorithm that parallels the molecular separation of PTCL-NOS and provides useful prognostic information.
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
Fitzmaurice, Christina , Abate, Degu , Abbasi, Naghmeh , Abbastabar, Hedayat , Abdelalim, Ahmed , Abdoli, Amir , Abdulle, Abdishakur S. M., Abebe, Nebiyu Dereje , Abraha, Haftom Niguse , Abualhasan, Ahmed , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Afarideh, Mohsen , Afshari, Mahdi , Aghaali, Mohammad , Agius, Dominic, Agrawal, Sutapa , Ahmadi, Ayat , Ahmed, Muktar Beshir , Akbari, Mohammad Esmaeil , AlAbdulKader, Assim M. , Alahdab, Fares , Alam, Shazia , Alamene, Genet Melak, Alene, Kefyalew Addis , Alipour, Vahid, Bakeshei, Fatemeh Allah, Almadi, Majid A. , Alsharif, Ubai , Alsowaidi, Shirina, Alvis‐Guzmán, Nelson , Amini, Saeed, Anbari, Zohreh , Anber, Nahla , Andrei, Cătălina Liliana , Anjomshoa, Mina, Ansari, Fereshteh, Ansariadi, Ansariadi , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Areri, Habtamu Abera , Artaman, Al, Asfaw, Ephrem Tsegay, Ashagre, Alebachew Fasil, Assadi, Reza , Atalay, Hagos Tasew , Ataro, Zerihun , Atique, Suleman , Ávila‐Burgos, Leticia , Avokpaho, Euripide , Awasthi, Ashish , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayanore, Martin Amogre , Ayele, Henok Tadesse, Babaee, Ebrahim , Bacha, Umar, Badawi, Alaa, Bagherzadeh, Mojtaba , Bagli, Eleni , Balakrishnan, Senthilkumar , Bärnighausen, Till , Battista, Robert J., Behzadifar, Meysam, Belay, Yared Belete , Berfield, Kathleen, Berhane, Adugnaw , Bernabé, Eduardo , Beuran, Mircea , Bhakta, Nickhill , Bhattacharyya, Krittika , Biadgo, Belete , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Bisignano, Catherine, Bitew, Helen , Bjørge, Tone , Bogale, Kassawmar Angaw , Bojia, Hunduma Amensisa, Borzì, Antonio Maria , Bou-Orm, Ibrahim R. , Brenner, Hermann , Brewer, Jerry D., Briko, Andrey , Брико, Н. И. , Bustamante-Teixeira, Maria Teresa , Butt, Zahid A , Carreras, Giulia , Carvalho, Félix , Castro, Clara , Castro, Franz , Catalá-López, Ferrán , Cerin, Ester , Chaiah, Yazan , Chanie, Wagaye Fentahun, Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chauhan, Neelima Singh, Chiang, Peggy Pei-Chia, Chichiabellu, Tesfaye Yitna , Chido‐Amajuoyi, Onyema Greg , Chimed‐Ochir, Odgerel , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Crowe, Christopher S. , Curado, María Paula , Dahlawi, Saad M A , Damiani, Giovanni , Darwish, Amira Hamed , Demissie, Birhanu Wondimeneh , Demoz, Gebre Teklemariam , Derakhshani, Afshin , Deribe, Kalkidan Solomon, Desai, Rupak , Desalegn, Beruk Berhanu , Dey, Subhojit , Dhimal, Meghnath , Díaz, Daniel , Dinberu, Mesfin Tadese, Djalalinia, Shirin, Drake, Thomas M , Dubljanin, Eleonora , Duken, Eyasu Ejeta, Effiong, Andem , Eftekhari, Aziz , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Elemineh, Demelash Abewa , Elkout, Hajer , Ellenbogen, Richard G. , Elsharkawy, Aisha , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Endries, Aman Yesuf , Eshrati, Babak, Fadhil, Ibtihal , Farzadfar, Farshad , Fentahun, Netsanet , Fernandes, Eduarda , Feyissa, Garumma Tolu , Fischer, Florian , Fisher, James L. , Force, Lisa M , Freitas, Marisa , Fukumoto, Takeshi , Futran, Neal D. , Gallus, Silvano , Gankpé, Fortuné Gbètoho , Gayesa, Reta Tsegaye, Gebrehiwot, Tsegaye Tewelde , Gebremeskel, Gebreamlak Gebremedhn , Gedefaw, Getnet , Gelaw, Belayneh K., Geta, Birhanu, Getachew, Sefonias , Gezae, Kebede Embaye , Ghafourifard, Mansour , Ghajar, Alireza , Ghashghaee, Ahmad , Gholamian, Asadollah , Ginindza, Themba G. , Girmay, Alem, Gizaw, Muluken , Gomez, Ricardo Santiago , Gopalani, Sameer Vali , Gorini, Giuseppe , Goulart, Bárbara Niegia Garcia de , Grada, Ayman , Guerra, Maximiliano Ribeiro, Guimarães, André Luiz Sena , Gupta, Prakash C. , Hadkhale, Kishor , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hamidi, Samer , Hanfore, Lolemo Kelbiso , Hasankhani, Milad , Hasanzadeh, Amir , Hassen, Hamid Yimam , Hay, Simon I , Henok, Andualem , Herţeliu, Claudiu , Hoang, Chi Linh , Hole, Michael K., Hoogar, Praveen , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela, Hostiuc, Sorin , Househ, Mowafa , Hussen, Mohammedaman Mama, Ileanu, Bogdan Vasile , Ilić, Milena , Innos, Kaire , Irvani, Seyed Sina Naghibi , Iseh, Kufre Robert , Islam, Sheikh Mohammed Shariful , Balalami, Nader Jafari, Jafarinia, Morteza , Jahangiry, Leila , Jahanmehr, Nader , Jakovljević, Mihajlo, James, Spencer L , Jayaraman, Sudha , Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Jürisson, Mikk , Kamangar, Farin , Karimi, Narges , Karimian, Ansar , Kasaeian, Amir , Kasahun, Gebremicheal Gebreslassie , Kassa, Belete, Kassaw, Mesfin Wudu , Kaul, Anil, Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khalilarjmandi, Maryam, Khan, Ejaz Ahmad , Khan, Gulfaraz , Khang, Young-Ho, Khater, Amir M, Khayamzadeh, Maryam , Khazaee-Pool, Maryam , Khosravi, Mohammad Hossein , Khubchandani, Jagdish , Kianipour, Neda, Kim, Daniel , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Krohn, Kristopher J, Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kuupiel, Desmond , Lad, Deepesh , Lake, Eyasu Alem , Lakew, Ayenew Molla , Lal, Dharmesh Kumar, Lami, Faris , Lan, Qing , Lasrado, Savita , Lazarus, Jeffrey V. , Leigh, James , Leshargie, Cheru Tesema , Liao, Yu , Limenih, Miteku Andualem , Listl, Stefan , Lopukhov, Platon D , Lunevičius, Raimundas , Madadin, Mohammed , Razek, Hassan Magdy Abd El , Majeed, Azeem , Manafi, Ali, Manafi, Navid , Manamo, Wondimu Ayele, Mantovani, LG , Martini, Santi , Mashamba-Thompson, Tivani P. , Massenburg, Benjamin B. , Maswabi, Motswadi Titus, McAlinden, Colm , Meheretu, Hailemariam Abiy Alemu , Mehrotra, Ravi , Meles, Gebrekiros Gebremichael , Meles, Hagazi Gebre , Melku, Mulugeta , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Merat, Shahin , Meretoja, Tuomo J , Miazgowski, Bartosz , Miazgowski, Tomasz , Mihretie, Kebadnew Mulatu M., Miller, Ted R. , Mills, Edward J , Mir, Seyed Mostafa , Mishra, Rashmi , Moazen, Babak , Mohammad, Dara K., Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Moslem, Mohammadian, Mahdi , Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Ammas Siraj , Mohammed, Jemal , Mohammed, Shafiu , Mohebi, Farnam , Mokdad, Ali H. , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moossavi, Maryam , Moradi, Ghobad , Moradi-Joo, Mohammad , Moradpour, Farhad , Morawska, Lídia , Morgado-da-Costa, Joana, Mosapour, Abbas , Mousavi, Seyyed Meysam , Muche, Achenef Asmamaw , Muhammed, Oumer Sada , Musa, Jonah , Nabhan, Ashraf , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Nagel, Gabriele , Naik, Gurudatta , Nam, Hae‐Sung , Nazari, Javad , Negoi, Ionuţ , Neupane, Subas , Nggada, Haruna Asura , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikniaz, Leila , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Nixon, Molly R, Nnaji, Chukwudi A , Shiadeh, Malihe Nourollahpour , Obsa, Mohammed Suleiman , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olagunju, Tinuke O , Oluwasanu, Mojisola , Omonisi, Abidemi , Onwujekwe, Obinna , Oommen, Anu Mary , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakpour, Amir H. , Pană, Adrian , Park, Eun‐Kee , Patel, Shanti, Patil, Snehal T, Pennini, Alyssa, Piccinelli, Cristiano, Pillay, Julian David , Pirestani, Majid , Postma, Maarten J. , Pourmalek, Farshad , Pourshams, Akram , Prakash, Swayam , Rabiee, Navid , Radfar, Amir , Rafiei, Alireza , Rahim, Fakher , Rahimi, Mahdi , Rahman, Muhammad Aziz , Rajati, Fatemeh , Rana, Saleem M., Raoofi, Samira , Rath, Goura Kishor, Rawaf, David Laith , Reiner, Robert C. , Renzaho, André M. N. , Rezapour, Aziz, Ribeiro, Ana Isabel , Ribeiro, Daniela , Roro, Elias Merdassa , Rostami, Ali , Saad, Ragy , Sabbagh, Parisa , Saddik, Basema , Safiri, Saeid , Salahshoor, Mohammad Reza , Salehi, Farkhonde , Salem, Hosni , Salem, Marwa Rashad , Salimzadeh, Hamideh , Salomon, Joshua A. , Samy, Abdallah M , Sanabria, Juan , Santric-Milicevic, Milena M , Sartorius, Benn , Sarveazad, Arash , Sathian, Brijesh , Satpathy, Maheswar , Savic, Miloje , Sawhney, Monika, Seyedmousavi, Seyedmojtaba , Shaahmadi, Faramarz , Shabaninejad, Hosein , Shahbaz, Mohammad , Shaikh, Masood Ali, Shamshirian, Amir , Shamsizadeh, Morteza , Sharafi, Zeinab , Sharifi, Ali , Sharifi, Hamid , Shirkoohi, Reza , Shukla, Sharvari , Si, Si , Siabani, Soraya , Silva, Diego Augusto Santos , Singh, Ambrish , Sisay, Solomon , Sobngwi, Eugène , Soofi, Moslem , Soriano, Joan B. , Stathopoulou, Vasiliki, Sufiyan, Mu’awiyyah Babale , Tabarés‐Seisdedos, Rafael , Tabuchi, Takahiro , Takahashi, Ken , Tarawneh, Mohammed Rasoul , Tassew, Segen Gebremeskel , Taymoori, Parvaneh , Temsah, Mohamad‐Hani , Temsah, Omar, Tesfay, Fisaha Haile , Teshale, Manaye Yihune, Tessema, Gizachew Assefa , Thapa, Subash , Tlaye, Kenean Getaneh , Topór-Mądry, Roman , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Khanh Bao , Tsadik, Afewerki Gebremeskel , Ullah, Irfan , Vaezi, Maryam, Pérez, Patricia Varona , Vidale, Simone , Violante, Francesco Saverio , Vollset, Stein Emil, Vos, Theo , Vosoughi, Kia , Vu, Giang Thu , Vujcic, Isidora S , Wabinga, Henry, Wachamo, Tesfahun Mulatu , Wagnew, Fasil Shiferaw, Waheed, Yasir , Weldegebreal, Fitsum , Weldesamuel, Girmay Teklay, Wijeratne, Tissa , Wonde, Tewodros Eshete , Workie, Hailemariam Mekonnen , Yadav, Rajaram , Yadegar, Abbas , Yadollahpour, Ali , Yaseri, Mehdi , Yazdi‐Feyzabadi, Vahid , Yeshaneh, Alex , Yimam, Mohammed , Yisma, Engida , Younis, Mustafa Z , Zadnik, Vesna, Moghadam, Telma Zahirian , Zandian, Hamed , Zangeneh, Alireza , Zaki, Leila , Zendehdel, Kazem , Zenebe, Zerihun Menlkalew, Zewale, Taye Abuhay , Ziapour, Arash , Zodpey, Sanjay , Murray, Christopher J L , Topór‐Mądry, Roman , Deribe, Kebede , Teklay, Girmay , Wijeratne, T , Kumar, Vivek , Lazarus, Jeffrey V , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Abd-Allah, Foad , Abdel-Rahman, Omar Mohammed , Abdollahpour, Ibrahim , Abu-Raddad, Laith Jamal , Ahmadian, Elham , Ahmadpour, Ehsan , Akinyemiju, Tomi , Al‐Aly, Ziyad , Alemnew, Birhan , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Erfan , Amini, Saeed, Amoako, Yaw Ampem , Arab-Zozani, Morteza , Asayesh, Hamid , Fasil, Alebachew , Ataeinia, Bahar , Ausloos, Marcel , Balouchi, Abbas , Behzadifar, Masoud , Behzadifar, Meysam, Bekele, Bayu Begashaw , Belayneh, Yaschilal Muche , Birungi, Charles , Bleyer, Archie , Bosetti, Cristina , Carrero, Juan Jesús , Chaturvedi, Pankaj , Chehrazi, Mohammad , Constantin, María Magdalena , Crocetti, Emanuele , Daryani, Ahmad , Neves, José das , Demeke, Feleke Mekonnen , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Deribe, Kalkidan Solomon, Desta, Melaku , Dharmaratne, Samath Dhamminda , Doku, David Teye , Dubey, Manisha , Ebrahimi, Hedyeh , Sayed, Iman El , Zaki, Maysaa El Sayed , Adane, Daniel, Omrani, Vahid Fallah , Faramarzi, Mahbobeh , Farhangi, Mahdieh Abbasalizad , Farioli, Andrea , Filip, Irina , Foroutan, Masoud , Tsegaye, Reta , Gelaw, Belayneh K., Gill, Paramjit Singh , Gupta, Rahul, Haro, Josep María , Hay, Roderick J. , Henry, Nathaniel J , Hidru, Hagos Degefa , Horita, Nobuyuki , Hosgood, H. Dean, Hostiuc, Mihaela, Hussen, Mohammedaman Mama, Islami, Farhad , Jahani, Mohammad Ali , Jakovljević, Mihajlo , Javanbakht, Mehdi , Jee, Sun Ha , Jenabi, Ensiyeh , Jonnagaddala, Jitendra, Jungari, Suresh Banayya , Kabir, Ali , Karch, André , Kassa, Tesfaye , Kerbo, Amene Abebe , Khang, Young-Ho, Khatab, Khaled , Khazaei, Salman , Khoja, Abdullah T , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Vecchia, Carlo La , Lal, Dharmesh Kumar, Lauriola, Paolo , Lopez, Alan D , Magdeldin, Sameh , Maleki, Afshin , Malekzadeh, Reza , Manamo, Wondimu Ayele, Mansourian, Morteza , Mansournia, Mohammad Alì , Maroufizadeh, Saman , Mathur, Manu Raj , McKee, Martin , Mehta, Varshil , Meier, Toni , Melaku, Yohannes Adama , Melese, Addisu Dagnaw , Meštrović, Tomislav , Mulatu, Kebadnew , Mirzaei, Hamed , Mirzaei, Hamid Reza , Mohammad, Dara K., Darwesh, Aso Mohammad , Mohammadbeigi, Abolfazl , Mohammadi, Hiwa , Mohammadi, Moslem, Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Nahvijou, Azin , Najafi, Farid , Naldi, Luigi , Nasiri, Naser , Newcomb, Polly A. , Nojomi, Marzieh , Nosratnejad, Shirin , Oh, In‐Hwan , Oren, Eyal , Ota, Erika , Owolabi, Mayowa , Parsian, Hadi , Pashaei, Tahereh , Pereira, David M. , Pishgar, Farhad , Pourjafar, Hadi , Prasad, Narayan , Qorbani, Mostafa , Rabiee, Mohammad , Rana, Saleem M., Rawaf, Salman , Rezaei, Nima , Ronfani, Luca , Roshandel, Gholamreza , Saad, Ragy , Sabbagh, Parisa, Sabour, Siamak , Sahebkar, Amirhossein , Sayyah, Mehdi , Schneider, Ione Jayce Ceola , Schöttker, Ben , Šekerija, Mario , Sepanlou, Sadaf Ghajarieh , Sepehrimanesh, Masood , Sharafi, Heidar , Sharif, Mehdi , Sharma, Rajesh , Sheikh, Aziz , Silveira, Dayane Gabriele Alves , Singh, Jasvinder A. , Sitas, Freddy , Tamtaji, Omid Reza , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Teshale, Manaye Yihune, Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Vacante, Marco , Vaezi, Maryam, Veisani, Yousef , Vlassov, Vasily , Vollset, Stein Emil, Wagnew, Fasil , Wondafrash, Dawit Zewdu , Wondmieneh, Adam Belay , Yimer, Ebrahim M , Yonemoto, Naohiro , Yousefi, Bahman , Yousefifard, Mahmoud , Yu, Chuanhua , Zabeh, Erfan , Zaidi, Zoubida , Zamani, Mohammad , Olagunju, Andrew T , Bhakta, Nickhill , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

JAMA Oncology | September 27, 2019 | Volume: 5 | Issue: 12 | Pages: 1749

10.1001/jamaoncol.2019.2996 | PMID 31560378 Get It

Slow‐channel myasthenia due to novel mutation in M2 domain of AChR delta subunit
Shen, Xin‐Ming , Milone, Margherita , Wang, Hang Long, Banwell, Brenda, Selcen, Duygu , Sine, Steven M. , Engel, Andrew G. , Shen, Xin-Ming

Mayo Clinic

Annals of Clinical and Translational Neurology | September 27, 2019 | Volume: 6 | Issue: 10 | Pages: 2066-2078

10.1002/acn3.50902 | PMID 31560172 Get It

AbstractObjectiveTo characterize the molecular and phenotypic basis of a severe slow‐channel congenital myasthenic syndrome (SCCMS).MethodsIntracellular and single‐channel recordings from patient endplates; alpha‐bungarotoxin binding studies; direct sequencing of AChR genes; microsatellite analysis; kinetic analysis of AChR activation; homology modeling of adult human AChR structure.ResultsAmong 24 variants reported to cause SCCMS only two appear in the AChR δ‐subunit. We here report a 16‐year‐old patient harboring a novel δL273F mutation (δL294F in HGVS nomenclature) in the second transmembrane domain (M2) of the AChR δ subunit. Kinetic analyses with ACh and the weak agonist choline indicate that δL273F prolongs the channel opening bursts 9.4‐fold due to a 75‐fold increase in channel gating efficiency, whereas a previously identified εL269F mutation (εL289F in HGVS nomenclature) at an equivalent location in the AChR ε‐subunit prolongs channel opening bursts 4.4‐fold due to a 30‐fold increase in gating efficiency. Structural modeling of AChR predicts that inter‐helical hydrophobic interactions between the mutant residue in the δ and ε subunit and nearby M2 domain residues in neighboring α subunits contribute to structural stability of the open relative to the closed channel states.InterpretationThe greater increase in gating efficiency by δL273F than by εL269F explains why δL273F has more severe clinical effects. Both δL273F and εL269F impair channel gating by disrupting hydrophobic interactions with neighboring α‐subunits. Differences in the extent of impairment of channel gating in δ and ε mutant receptors suggest unequal contributions of ε/α and δ/α subunit pairs to gating efficiency.
Fluorescence in‐situ hybridisation for TP63 rearrangements in T cell lymphomas: single‐site experience of 470 patients and implications for clinical testing
Peterson, Jess F. , Pearce, Kathryn E., Meyer, Reid G., Greipp, Patricia T. , Knudson, Ryan A., Feldman, Andrew L. , Feldman, Andrew L , Peterson, Jess F , Greipp, Patricia T , Baughn, Linda B. , Ketterling, Rhett P.

Mayo Clinic

Histopathology | September 27, 2019 | Volume: 76 | Issue: 3 | Pages: 481-485

10.1111/his.14005 | PMID 31557339 Get It

AimsThe aims of this study were to review our 5‐year experience with clinical FISH testing for TP63 rearrangements using both TP63 break‐apart (BAP) and TBL1XR1/TP63 dual‐fusion (D‐FISH) probes to evaluate the frequency of TP63 rearrangements and the distribution of TBL1XR1 vs. alternate partner loci, and to assess whether both probe sets are necessary in all cases undergoing FISH testing.Methods and resultsA retrospective review of the Mayo Clinic cytogenetic database identified 470 patients evaluated by FISH testing for TP63 rearrangements in formalin‐fixed paraffin‐embedded (FFPE) tissue using both BAP and D‐FISH probes. Of these, 25 (5.3%) had TP63 rearrangements. All samples were being investigated for anaplastic large‐cell lymphoma or other T cell lymphoma subtypes. A TBL1XR1 partner was identified by D‐FISH in 12 (48%) of 25 cases. All cases positive by TBL1XR1/TP63 D‐FISH were also positive by TP63 BAP FISH.ConclusionThis is the largest series of TP63 rearrangements to date. The frequency of positive results among cases referred to a large reference laboratory for TP63 FISH testing was 5.3%. Approximately half of TP63 rearrangements have a TBL1XR1 partner. TP63 BAP FISH testing is sufficient for up‐front testing of FFPE tissue samples. However, because of the genomic proximity of the TP63 and TBL1XR1 loci, we recommend reflex TBL1XR1/TP63 D‐FISH testing in positive and equivocal cases.
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry
Xian, Ying , Li, Zhuokai , Robinson, Jennifer G. , Louie, Michael J. , Koren, Andrew , Goldberg, Anne C. , Roger, Véronique L. , Wilson, Peter W.F. , Wang, Tracy Y., Návar, Ann Marie , Li, Shuang, Virani, Salim S. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 26, 2019 | Volume: 8 | Issue: 19 | Pages: No page available

10.1161/jaha.119.013229 | PMID 31554462 Get It

Background Current treatment guidelines strongly recommend statin therapy for secondary prevention. However, it remains unclear whether patients’ perceptions of cardiovascular risk, beliefs on cholesterol, or the intensity of prescribed statin therapy differs for patients with coronary artery disease ( CAD ) versus cerebrovascular disease (Ce VD ) versus both CAD and Ce VD ( CAD &Ce VD ). Methods and Results The PALM (Patient and Provider Assessment of Lipid Management) registry collected data on statin use, intensity, and core laboratory low‐density lipoprotein cholesterol levels for 3232 secondary prevention patients treated at 133 US clinics. Among individuals with Ce VD only (n=403), CAD only (n=2202), and Ce VD & CAD (n=627), no significant differences were observed in patient‐perceived cardiovascular disease risk, beliefs on cholesterol lowering, or perceived effectiveness and safety of statin therapy. However, patients with Ce VD only were less likely to receive any statin therapy (76.2% versus 86.2%; adjusted odds ratio 0.64, 95% CI 0.45–0.91), or guideline‐recommended statin intensity (34.6% versus 50.4%; adjusted odds ratio 0.60, 95% CI 0.45–0.81) than those with CAD only. Individuals with Ce VD only were also less likely to achieve low‐density lipoprotein cholesterol <100 mg/ dL (59.2% versus 69.7%; adjusted odds ratio 0.79, 95% CI 0.64–0.99) than individuals with CAD alone. There were no significant differences in the use of any statin therapy or guideline‐recommended statin intensity between individuals with CAD &Ce VD and those with CAD only. Conclusions Despite lack of significant differences in patient‐perceived cardiovascular risk or statin beliefs, patients with Ce VD were significantly less likely to receive higher intensity statin or achieve low‐density lipoprotein cholesterol <100 mg/ dL than those with CAD only.
Analysis of 90-Day Readmissions After Total Shoulder Arthroplasty
Chung, Andrew S. , Makovicka, Justin L. , Hydrick, Thomas C. , Scott, Kelly, Cho, Samuel , Hattrup, Steven J. , Hydrick, Thomas, Scott, Kelly L, Chung, Andrew

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 24, 2019 | Volume: 7 | Issue: 9 | Pages: No page available

10.1177/2325967119868964 | PMID 31579681 Get It

Background: The number of total shoulder arthroplasty (TSA) procedures performed annually is increasing as a result of an aging population and an increased access to subspecialty-trained upper extremity arthroplasty surgeons. An up-to-date analysis of the incidence of, risk factors for, and reasons for 90-day readmissions in primary anatomic TSA has yet to be performed. Purpose: To characterize 90-day readmissions on a national level. An understanding of these data will help to predict resource utilization and expenses in shoulder arthroplasty. Study Design: Case-control study; Level of evidence, 3. Methods: All adult patients undergoing elective primary TSA in 2014 who were included in the National Readmission Database were included in the analysis. Two cohorts were created according to 90-day readmission status. Multivariable analysis was then performed to determine predictors of 90-day readmissions. Reasons for 30-, 60-, and 90-day readmissions were identified, and total hospital resource utilization was calculated. Results: An estimated 26,023 patients were identified. The 30-, 60-, and 90-day rates of readmissions were 0.6%, 1.2%, and 1.7%, respectively. There was no difference in comorbidity burden between the cohorts. Medicare payer status (odds ratio [OR], 1.63; 95% CI, 1.00-2.65; P = .05), transfer to a skilled nurse facility (OR, 1.50; 95% CI, 1.05-2.14; P = .02), and chronic obstructive pulmonary disease (OR, 1.32; 95% CI, 1.04-1.66; P = .02) were identified as predictors of 90-day readmission. Female sex decreased odds of 90-day readmission (OR, 0.72; 95% CI, 0.59-0.87; P = .001). Ninety-day readmissions were associated with significant cost increases ( P < .001). The most common identifiable reason for related readmissions was a hardware-related complication at all time points. Conclusion: While uncommon, 90-day readmissions after primary TSA are associated with significant patient morbidity and ultimately substantial hospital costs. Truncating readmission analysis at a 30-day period will miss most arthroplasty-related hospital readmissions.
Contrast enhanced ultrasound characterization of surgically resected renal masses in patients on dialysis
Kahn, Amanda E. , Ostrowski, A., Caserta, Melanie P. , Galler, Isabella, Thiel, David D. , Ostrowski, Andrew K, Galler, Isabella J, Kahn, Amanda

Mayo Clinic

Scandinavian Journal of Urology | September 24, 2019 | Volume: 53 | Issue: 5 | Pages: 344-349

10.1080/21681805.2019.1666917 | PMID 31549563 Get It